Pharmacogenetic profiling for oxaliplatin-based adjuvant chemotherapy (CT) benefit in stage II-III colon cancer (CC) patients: A GEMCAD study.Jaime Feliú, Paloma Cejas, Ana Custodio et al.|Journal of Clinical Oncology|2012Cited by 0
Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study.Ana Custodio, Carlos Fernández-Martos, Ricardo Yayá et al.|Journal of Clinical Oncology|2012Cited by 0
Purified Human Pancreatic Islets, CIT Culture Media with Lisofylline or Exenatide.J Ansite, A N Balamurugan, B Barbaro et al.|PubMed|2017Cited by 0